Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 57

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 57
---
 Committee and Board determined this reduced bonus taking into account the early termination of the TROPOS trial in January 2025 based on an ongoing safety review due to the unanticipated observation of pericardial effusion adverse events in the trial, among other factors. Upon the Compensation Committee’s recommendation, the Board approved an additional discretionary bonus for Dr. Chyung in the amount of $11,320, reflecting our Compensation Committee’s and our Board’s subjective consideration of his significant individual contributions to the Company, including his leadership

40

TABLE OF CONTENTS

in directing a select group of unblinded individuals at Keros to complete the risk and benefit assessment of the data from the TROPOS trial. This discretionary payment is reported in the “Bonus” column in the Summary Compensation Table. The table below reflects each named executive officer’s annual performance bonus for 2024 (and includes, with respect to Dr. Chyung, his additional discretionary bonus):

| Named Executive Officer   | ​ | ​ | Total IncentiveAmount Paid ($) |   |         |   | ​ |
| Jasbir Seehra, Ph.D.      | ​ | ​ | ​                              | ​ | 455,000 | ​ | ​ |
| Keith Regnante            | ​ | ​ | ​                              | ​ | 197,142 | ​ | ​ |
| Yung Chyung, M.D.         | ​ | ​ | ​                              | ​ |  67,320 | ​ | ​ |
| Simon Cooper, M.B.B.S.(1) | ​ | ​ | ​                              | ​ |       — | ​ | ​ |
| Christopher Rovaldi       | ​ | ​ | ​                              | ​ | 297,000 | ​ | ​ |

(1) On February 29, 2024, Dr. Cooper resigned from his position as our Chief Medical Officer, effective March 12, 2024. As a result, Dr. Cooper was not entitled to an annual performance bonus for 2024. Equity Compensation We believe that our ability to grant equity awards is a valuable and necessary compensation tool that aligns the financial interests of our executive officers and our stockholders. In addition, we believe that our ability to grant equity awards helps us to attract, retain and motivate executive officers, and fosters an ownership culture, designed to incentivize them to devote their best efforts to the success of our business. As such, our executives generally are awarded an initial grant upon commencement of employment, as well as